Revvity Beats Q4 Forecasts, Sets Bullish 2026 Targets on Diagnostics Strength
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.